This trial is examining the effectiveness and safety of standard chemoradiation vs a PET base chemoradiation combination in patients with non-small cell lung carcinoma (NSCLC). The main outcomes to be measured will be side effects and survival without cancer growing or spreading.
A treatment option for patients with NSCLC is standard chemoradiation. This involves chemotherapy and radiation therapy. Standard chemoradiation can be long. An alternative is to treat with PET-based chemoradiation (chemoradiation combined with an imaging technique to help diagnose the progression of the cancer). This option is more personalized and may be shorter. It is not known if PET-based chemoradiation is more effective and safe at treating NSCLC.
This study is being done to investigate the effectiveness and safety of standard chemoradiation vs a PET-based chemoradiation combinationin patients with NSCLC. The main outcomes to be measured will be side effects and survival without cancer growing or spreading.
Who are they looking for?
50 participants NSCLC will be recruited. Patients must have a biopsy to confirm NSCLC, and have a PET and MRI before entry. They must not have had prior chemotherapy or radiotherapy for lung cancer and must have normal bone marrow and organ function. Women must have a negative pregnancy test and be on adequate birth control throughout the trial.
Patients cannot participate if they have pleural or pericardial effusion or poorly controlled diabetes. Participants must not be prisoners or detained for infectious diseases.
How will it work
There will be two groups. Group 1 will receive standard chemoradiation over 6 weeks. Group 2 will receive chemoradiation with PET imaging, over 4 weeks.